PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11227992-9	2000	3TC plus ddC resulted in greater p24 inhibition than 3TC or ddC alone (P<0.001).	Zalcitabine	9-12	transmembrane p24 trafficking protein 2	Homo sapiens	33-36	
11227992-10	2000	Combining one thymidine analogue (ZDV or d4T) with one cytidine analogue (3TC or ddC) resulted in greater inhibition of p24 inhibition than with any single agent.	Zalcitabine	81-84	transmembrane p24 trafficking protein 2	Homo sapiens	120-123	
8697399-13	1996	CONCLUSIONS: Combination antineoplastic and zalcitabine antiretroviral therapy may be safely administered to patients with AIDS-related lymphoma, resulting in CR in 56%, lack of significant neurotoxicity, and favorable effect on HIV p24 antigen in 50%.	Zalcitabine	44-55	transmembrane p24 trafficking protein 2	Homo sapiens	233-236	
7614775-7	1995	A variety of clinical trials have evaluated the efficacy of zalcitabine based on improved survival and decreased frequency of opportunistic infections and on a surrogate marker of HIV disease, the CD4 count, or the concentration of an antigen associated with HIV, p24.	Zalcitabine	60-71	transmembrane p24 trafficking protein 2	Homo sapiens	264-267	
7614775-8	1995	Alternating zalcitabine therapy with zidovudine therapy was associated with increased CD4+ lymphocyte counts and reduced plasma p24 antigen levels.	Zalcitabine	12-23	transmembrane p24 trafficking protein 2	Homo sapiens	128-131	
7840911-5	1994	MONOTHERAPY STUDIES: Zalcitabine at 0.005 or 0.01 mg/kg three times a day was associated with stabilization of growth and a decline in p24 antigen levels in more than 50% of treated children.	Zalcitabine	21-32	transmembrane p24 trafficking protein 2	Homo sapiens	135-138	
1281077-5	1992	In clinical trials, p24 antigen levels decreased and CD4 cell counts increased in patients with acquired immunodeficiency syndrome (AIDS) receiving zalcitabine > or = 0.03 mg/kg/day as monotherapy.	Zalcitabine	148-159	transmembrane p24 trafficking protein 2	Homo sapiens	20-23	
8097417-12	1993	When used as primary therapy in patients with CD4+ < or = 300 cells/mm3, ddC/ZDV increased CD4+ lymphocyte counts and reduced plasma p24 antigen concentrations.	Zalcitabine	76-79	transmembrane p24 trafficking protein 2	Homo sapiens	136-139	
2159703-5	1990	The studies discussed here indicate that low-dose ddC treatment regimens substantially reduce the toxic side effects of this drug, and yet retain the ability to affect p24 antigen and CD4+ lymphocyte levels.	Zalcitabine	50-53	transmembrane p24 trafficking protein 2	Homo sapiens	168-171	
2536257-0	1989	Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections.	Zalcitabine	48-63	transmembrane p24 trafficking protein 2	Homo sapiens	12-15